Accessibility Menu
REMSleep logo

REMSleep(OTC) RMSL

Market Cap$2.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2010)-100%
5 Year-84%
1 Year-75%
1 Month-26%
$0.00
-15%
-0.00Today
REMSleep last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
REMSleep stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.49%USD 0.002026-07-22
1 month-26.09%USD 0.002026-06-29
3 month-62.22%USD 0.002026-04-30
Year to date+0%USD 0.002025-12-31
1 year-75.29%USD 0.012025-07-29
3 year-85.83%USD 0.012023-07-28
5 year-83.65%USD 0.012021-07-30
Since inception-99.99%USD 13.402010-06-08

REMSleep Financials at a Glance

Market Cap

$2.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$16.72K

Net Income (TTM)

-$3.02T

EPS (TTM)

-$0.00

P/E Ratio

-0.85

Dividend

$0.00

Beta (Volatility)

-0.04 (Low)

Price

$0.00

Volume

2,530,122

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.01

Estimated Earnings Date

Apr 13, 2026

RMSL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About REMSleep

REMSleep makes devices for people with sleep apnea, a common breathing disorder. Its main product helps users breathe easier at night. The company’s solutions aim to improve comfort for patients and support healthcare providers.

Gadgets for a Good Night: REMSleep’s Offerings

  • DeltaWave CPAP Interface: Nasal device for sleep apnea therapy; 100% of Q2 2025 revenue; targets patients, clinics, and home care providers.
  • ResPlus Auto CPAP Machine: Discontinued in late 2024; previously used for sleep apnea treatment; served clinics and end users.

Growth Spurts and Strategic Moves

  • Received FDA 510(k) approval for DeltaWave in July 2024, enabling U.S. sales.
  • Discontinued ResPlus CPAP machine at end of 2024 to focus on DeltaWave.
  • Relocated to a smaller, lower-cost facility in Blackshear, Georgia in June 2025.
  • Shifted business model from product development to commercialization in 2025.

What Makes REMSleep Stand Out

REMSleep’s patented DeltaWave device aims to address common comfort issues in sleep apnea therapy. The company’s leadership brings decades of sleep industry experience. Its focus is on improving patient compliance and reducing discomfort with unique airflow design.

Five Things You Need to Know

  • Q2 2025 revenue was $4,824, down 82.5% from Q2 2024.
  • All Q2 2025 revenue came from the DeltaWave device.
  • Net loss for Q2 2025 was $287,772, a 27.3% greater loss than Q2 2024.
  • Cash used in operations for first half 2025 was $251,368.
  • As of June 2025, all receivables were from one customer, increasing risk.

Bottom Line

REMSleep is a small medical device company focused on a single patented product. The business faces financial challenges but is adapting by narrowing its focus and reducing costs.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

2

CEO

Jeffrey Marshall

Website

www.remsleep.com

Headquarters

Blackshear, GA 33607, US

RMSL Financials

Key Financial Metrics (TTM)

Gross Margin

-20.06%

Operating Margin

-17150.92%

Net Income Margin

-18062916120.06%

Return on Equity

-4042468745.17%

Return on Capital

-2505.50%

Return on Assets

-1351292192.11%

Earnings Yield

-1.18%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.69B

Volume

2.53M

Avg. Volume

2.13M

Financials (TTM)

Gross Profit

-$3.36K

Operating Income

-$2.87M

EBITDA

-$2.93M

Operating Cash Flow

-$502.83B

Capital Expenditure

$2.00

Free Cash Flow

-$502.83B

Cash & ST Invst.

$87.95K

Total Debt

$36.86K

REMSleep Performance Analysis

REMSleep annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 320,719N/A
20232023-12-31USD 203,718-36.5%
20242024-12-31USD 117,185-42.5%
20252025-12-31USD 16,721-85.7%
REMSleep sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-3054.5%
Q42025-12-31-40.4%
Q12026-03-31-100.0%
REMSleep annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.00-81.8%
20232023-12-31USD -0.0020.0%
20242024-12-31USD -0.00-41.7%
20252025-12-31USD -0.00171.4%
REMSleep sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30-650.0%
Q42025-12-31-128431233.3%
Q12026-03-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$7.37K

-52.4%

Gross Margin

0.00%

N/A

Market Cap

$2.88MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.44M

N/A

Employees

2

N/A

Net Income

-$289.92K

-239.1%

EBITDA

-$223.98K

-5084.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$87.95K

-82.7%

Total Debt

$36.86K

-57.7%

Accounts Receivable

$0.00

-100.0%

Inventory

$70.36K

N/A

Long Term Debt

$3.79K

N/A

Short Term Debt

$33.07K

-62.1%

Return on Assets

-13512921.92%

N/A

Return on Invested Capital

24.15%

N/A

Free Cash Flow

-$176.56K

-60.4%

Operating Cash Flow

-$176.56K

-60.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
LLBOLifeline Biotechnologies, Inc.
$0.00+0.00%
TGIFF1933 Industries Inc.
$0.00+14.52%
FZMDFuse Medical, Inc.
$0.02+0.00%
KOSKMetawells Oil & Gas Inc.
$0.00-29.64%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$19.63-0.20%
NOKNokia
$8.41-0.06%
SKHYSK Hynix
$126.79-0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$57.75-0.06%

Questions About RMSL

What is the current price of REMSleep?

REMSleep is trading at $0.00 per share.

What is the 52-week range for REMSleep?

Over the past 52 weeks, REMSleep has traded between $0.00 and $0.01.

How much debt does REMSleep have?

As of the most recent reporting period, REMSleep reported total debt of $36.86K.

How much cash does REMSleep have on hand?

REMSleep reported $87.95K in cash and cash equivalents in its most recent financial results.

What is REMSleep’s dividend yield?

REMSleep does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services